Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets Remsima, Truxima, and Herzuma products; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 1 clinical trial; CT-P17 for the treatment of rheumatoid arthritis, psoriatic arthritis, and IBD, which is in phase 3 clinical trial; CT-P16 for the treatment of metastatic colorectal cancer and breast cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 1 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; CT-P59 for the treatment of COVID-19, which is in phase 3 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial. Celltrion, Inc. has a partnership with Inhalon Biopharma, Inc. to develop IN-006, an inhaled form of regdanvimab for treating patients with COVID-19. The company was founded in 2002 and is headquartered in Incheon, South Korea.
Celltrion, Inc. (068270.KS) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 700.33 M | 951.52 M | 2 B | 14.29 B | 3.6 B |
| 2022 | 1.21 B | 173.07 M | 1.16 B | 4.23 B | 2.1 B |
| 2021 | 835.66 M | -318,631,670 | 1.17 B | 4.07 B | 2.21 B |
| 2020 | 1.01 B | 64.67 M | 1.14 B | 3.6 B | 1.81 B |
| 2019 | 593.34 M | -36,438,248 | 708.17 M | 2.77 B | 1.28 B |